Quebec-based non-for-profit organization engages Novateur experts for business development and scientific due diligence advisory support
Since 2017, IRICoR has engaged Novateur’s team of experts for a number of mandates. Those included Business Development advisory, Competitive Landscape Analysis, Scientific Due Diligence, and Market Assessment for a number of its projects. Novateur continues to support IRICoR on a number of projects, including those being spun-off into new companies.
One of these projects has been the Tumor Specific Neo-antigen technology developed by Dr. Claude Perreault and Dr. Pierre Thibault, both principal investigators at IRICoR.
Novateur was engaged to support business development of this technology in 2018 and assisted in out-licensing efforts. In 2021, together with top tiered Canadian and British VCs, Epitopea was founded in 2021 and and a seed round of $14M was raised in 2022.
For more information about Epitopea visit:
Claude Perreault and Pierre Thibault, founders of Epitopea, a company that offers hope for the treatment of cancer (Published on May 26, 2022)
Press Release (May 18, 2022): Novateur Ventures Participates in Founding and Financing of Epitopea, a New Cancer Therapeutics Company
"Novateur Ventures, a leading global life sciences advisory firm, announced it has participated in the $13.6M (£10.3M) seed investment raised by Epitopea, a cancer therapeutics company recently spun out of the Université de Montréal (UdeM) / IRIC in partnership with IRICoR. This investment will support the further development and application of Epitopea’s ground-breaking approaches to identify shared, aberrantly expressed tumor-specific antigens (TSA), that Epitopea has exclusively licensed from UdeM."